LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Strona główna・Stock List・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Closed

1.28 2.4

Buy Sell

Overview

Share price change

24h

Current

Min

1.28

Max

1.28

Key metrics
By Trading Economics
Income	17M -26M
Employees	171
EBITDA	19M -23M

Dividends
By Dow Jones
Next Earnings	26 lut 2026

Market Stats
By TradingEconomics
Market Cap	-34M 68M
Previous open	-1.12
Previous close	1.28

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

1.43 / 1.6 Support & Resistance

Pliant Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

22 lut 2026, 23:55 UTC

Market Talk

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

22 lut 2026, 23:53 UTC

Market Talk

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

22 lut 2026, 23:53 UTC

Market Talk

Key China Rates Likely to Be Held Steady for Now -- Market Talk

22 lut 2026, 23:51 UTC

Market Talk

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

22 lut 2026, 23:35 UTC

Market Talk

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

22 lut 2026, 23:21 UTC

Earnings

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

22 lut 2026, 23:20 UTC

Earnings

Nickel Industries 2025 Operating Profit US$126.4 Million

22 lut 2026, 23:19 UTC

Earnings

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

22 lut 2026, 23:19 UTC

Earnings

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

22 lut 2026, 23:18 UTC

Earnings

Nickel Industries Won't Pay a Final Dividend

22 lut 2026, 23:16 UTC

Earnings

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

22 lut 2026, 21:35 UTC

Earnings

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

22 lut 2026, 21:34 UTC

Earnings

Ampol Says F&I Australia, International Have Begun 2026 Strongly

22 lut 2026, 21:34 UTC

Earnings

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

22 lut 2026, 21:33 UTC

Earnings

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

22 lut 2026, 21:33 UTC

Earnings

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

22 lut 2026, 21:28 UTC

Earnings

Ampol Final Dividend A$0.60/Share

22 lut 2026, 21:28 UTC

Earnings

Ampol FY Revenue A$31.37 Billion, Down 10%

22 lut 2026, 21:28 UTC

Earnings

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

22 lut 2026, 21:28 UTC

Earnings

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

21 lut 2026, 14:31 UTC

Acquisitions, Mergers, Takeovers

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

21 lut 2026, 05:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

20 lut 2026, 23:12 UTC

Acquisitions, Mergers, Takeovers

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20 lut 2026, 22:12 UTC

Earnings

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

20 lut 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20 lut 2026, 21:23 UTC

Earnings

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20 lut 2026, 21:20 UTC

Market Talk

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20 lut 2026, 21:01 UTC

Acquisitions, Mergers, Takeovers

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20 lut 2026, 20:38 UTC

Market Talk

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Peer Comparison

Price change

Pliant Therapeutics Inc Forecast

Rating Consensus

By TipRanks

Sell

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Pliant Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.43 / 1.6Support & Resistance

Recent bearish events outweigh bullish events.

There is one bearish event.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.